• Used for 2-D image guidance • Typically acquired weekly (every 5 fractions)
• Doses of 1-5 cGy, depending on MU per field used • Doses ≤ 1 cGy per fraction (<1% of prescription dose) • In this scenario, accounting for dose in the treatment planning process is not necessary
Megavoltage Imaging Types and Doses (2) • Megavoltage Computed Tomography (MVCT), TomoTherapy IJROBP 70, 1579 IJROBP 70, -1587 IJROBP 70, (2008 Accounting for Imaging Dose in the Treatment Planning Process
• Not necessary for standardly-configured image guidance systems that are currently manufactured. o Assumes MV portal imaging is done once a week.
• May be needed for daily MV-CBCT, although MV-CBCT systems are no longer manufactured.
• Daily MV portal imaging at 2 MU per field may justify incorporating imaging dose into the treatment planning process.
Methods to Account for MV-CBCT Imaging Dose
(1) Calculate the dose with the treatment planning system and incorporate it, voxel-by-voxel, into the treatment plan 
MV-CBCT Organ Doses
• Extensive multi-site dose analysis reported by VanAntwerp et al, Med Dosimetry 36, 284-291 (2011) MV-CBCT Imaging Dose Incorporation
• Daily MVCBCT imaging dose calculated for all patients with >5 treatment fractions at the University of Iowa • 3D-CRT planning:
• If imaging dose at prescription point is 10 cGy/fx and the desired total dose is 180 cGy, scale treatment beam MUs such that 170 cGy is delivered with treatment beams.
• IMRT planning:
• Imaging dose is a beam with fixed MUs, and therapeutic beams are optimized "on top of" the imaging dose 
Future of Megavoltage Imaging
• 2-D MV imaging unlikely to go away anytime soon
• Dose is justifiable given the low magnitude and benefits • For large patients, 2-D kV images may be of poor quality
• TomoTherapy MVCT imaging dose is reasonable and does not need to be incorporated into treatment plans.
• 500 TomoTherapy units worldwide (confirmed by Accuray)
• Extent of MV-CBCT usage is unknown -product no longer sold by Siemens or any other vendor. End-of-life assumed to be 2022 -10 years after end of manufacturing.
• Varian has a 2.5 MV imaging beam product for TrueBeam 2.0 • Could MV Imaging be used to complement kV imaging? • TrueBeam 2.0 2.5 MV imaging beam, kV, and 6 MV image quality and dose metrics were compared.
• Dose lower for 2.5 MV than for 6 MV • SNR: Best for kV, then 2.5 MV, then 6 MV • Conclusions: kV images provide best image quality per unit dose • The 2.5 MV beam had excellent contrast at a lower dose than 6 MV and may be superior to kV for difficult to image areas that include large changes in anatomical thickness.
Conclusions
• Doses for MV-CBCT imaging can be high enough that imaging dose incorporation may be needed • Imaging dose incorporation is achievable with commercially-available treatment planning systems.
• The future of MV-CBCT is questionable. The modality appears to be nearing obsolescence.
• 2.5 MV beams for imaging are emerging and commercially available. 
